Cinctive Capital Management LP Invests $3.15 Million in United Therapeutics Corporation $UTHR

Cinctive Capital Management LP purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,507 shares of the biotechnology company’s stock, valued at approximately $3,147,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. AXQ Capital LP raised its holdings in shares of United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after acquiring an additional 3,235 shares in the last quarter. AE Wealth Management LLC grew its stake in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC increased its position in United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc acquired a new position in United Therapeutics in the 3rd quarter worth about $444,000. Finally, Simplify Asset Management Inc. purchased a new stake in shares of United Therapeutics during the 3rd quarter worth about $8,351,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $536.12 on Monday. The business’s 50-day simple moving average is $486.67 and its 200-day simple moving average is $462.28. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The firm has a market cap of $23.50 billion, a price-to-earnings ratio of 19.22, a P/E/G ratio of 1.93 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the company earned $6.19 EPS. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on UTHR shares. Royal Bank Of Canada lifted their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Cantor Fitzgerald increased their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $548.09.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $483.16, for a total value of $4,010,228.00. Following the transaction, the executive vice president owned 36,844 shares in the company, valued at $17,801,547.04. This trade represents a 18.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ray Kurzweil sold 4,910 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $489.02, for a total transaction of $2,401,088.20. Following the transaction, the director directly owned 12,670 shares of the company’s stock, valued at approximately $6,195,883.40. This represents a 27.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 307,930 shares of company stock valued at $150,132,812 in the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.